High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a highly heterogeneous malignancy with various outcomes, and therefore needs better risk stratification tools to help select optimal therapeutic options.

Methods

In this study, we identify miRNAs that could predict clinical outcome in a heterogeneous AML population using TCGA dataset.

Results

We found that MiR-363 is a novel prognostic factor in AML patients undergoing chemotherapy. In multivariable analyses, high miR-363 remained predictive for shorter OS (HR = 2.349, P = 0.012) and EFS (HR = 2.082, P = 0.001) independent of other well-known prognostic factors. More importantly, allogeneic hematopoietic stem cell transplantation (allo-HSCT) overcame the adverse outcomes related to high miR-363 expression. In gene expression

SUBMITTER: Zhang H 

PROVIDER: S-EPMC6444823 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature